JP2010507577A5 - - Google Patents

Download PDF

Info

Publication number
JP2010507577A5
JP2010507577A5 JP2009533536A JP2009533536A JP2010507577A5 JP 2010507577 A5 JP2010507577 A5 JP 2010507577A5 JP 2009533536 A JP2009533536 A JP 2009533536A JP 2009533536 A JP2009533536 A JP 2009533536A JP 2010507577 A5 JP2010507577 A5 JP 2010507577A5
Authority
JP
Japan
Prior art keywords
receptor tyrosine
tyrosine kinase
cancer
kinase
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009533536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507577A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/081832 external-priority patent/WO2008051805A2/en
Publication of JP2010507577A publication Critical patent/JP2010507577A/ja
Publication of JP2010507577A5 publication Critical patent/JP2010507577A5/ja
Withdrawn legal-status Critical Current

Links

JP2009533536A 2006-10-23 2007-10-18 トリアゾロピリダジンタンパク質キナーゼモジュレーター Withdrawn JP2010507577A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87138406P 2006-12-21 2006-12-21
US91375207P 2007-04-24 2007-04-24
US95283307P 2007-07-30 2007-07-30
PCT/US2007/081832 WO2008051805A2 (en) 2006-10-23 2007-10-18 Triazolo-pyridazine protein kinase modulators

Publications (2)

Publication Number Publication Date
JP2010507577A JP2010507577A (ja) 2010-03-11
JP2010507577A5 true JP2010507577A5 (enExample) 2010-12-02

Family

ID=39031065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533536A Withdrawn JP2010507577A (ja) 2006-10-23 2007-10-18 トリアゾロピリダジンタンパク質キナーゼモジュレーター

Country Status (16)

Country Link
US (1) US8071581B2 (enExample)
EP (1) EP2081937B1 (enExample)
JP (1) JP2010507577A (enExample)
KR (1) KR101083177B1 (enExample)
AU (1) AU2007309237B2 (enExample)
BR (1) BRPI0717317A2 (enExample)
CA (1) CA2667453A1 (enExample)
DK (1) DK2081937T3 (enExample)
EA (1) EA016527B1 (enExample)
ES (1) ES2393132T3 (enExample)
MX (1) MX2009004060A (enExample)
PE (1) PE20081256A1 (enExample)
PL (1) PL2081937T3 (enExample)
PT (1) PT2081937E (enExample)
TW (1) TW200833692A (enExample)
WO (1) WO2008051805A2 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7776905B2 (en) 2006-04-07 2010-08-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
ES2560435T3 (es) 2006-11-22 2016-02-19 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
PE20091468A1 (es) 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
MX393622B (es) 2008-05-21 2025-03-24 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
WO2010059771A1 (en) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
JP2012511575A (ja) * 2008-12-12 2012-05-24 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのアザインドール誘導体
DE102008063667A1 (de) * 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
CN102388048B (zh) * 2009-02-10 2014-07-30 阿斯利康(瑞典)有限公司 三唑并[4,3-b]哒嗪衍生物及其用于前列腺癌的用途
CA2754180A1 (en) 2009-03-09 2010-09-16 The Regents Of The University Of California Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
RS61281B1 (sr) * 2009-12-31 2021-02-26 Hutchison Medipharma Ltd Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
JP5714030B2 (ja) 2010-02-03 2015-05-07 インサイト コーポレーションIncyte Corporation C−Met阻害剤としてのイミダゾ[1,2−b][1,2,4]トリアジン
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105130948A (zh) * 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP3450432A1 (en) 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
EP2576544A4 (en) * 2010-06-01 2013-09-11 Angion Biomedica Corp INHIBITORS OF CYTOCHROMES P450 AND USES THEREOF
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
AU2012314501B2 (en) 2011-09-27 2017-02-16 Genfit Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
KR101869534B1 (ko) * 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
AP3908A (en) 2012-03-30 2016-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
CA2878057A1 (en) 2012-07-16 2014-01-23 Rossitza Gueorguieva Alargova Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
CN103122000B (zh) 2012-09-03 2013-12-25 中美冠科生物技术(太仓)有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
CN104884448A (zh) 2012-10-16 2015-09-02 詹森药业有限公司 Rorγt的杂芳基连接的喹啉基调节剂
JP6466335B2 (ja) 2012-10-16 2019-02-06 ヤンセン ファーマシューティカ エヌ.ベー. ROR−γ−Tのメチレン連結キノリニルモジュレーター
US9309222B2 (en) 2012-10-16 2016-04-12 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9846345B2 (en) 2013-02-28 2017-12-19 Empire Technology Development Llc Colored pigment particles for electrophoretic displays
EP3404032B1 (en) * 2013-03-13 2025-07-02 F. Hoffmann-La Roche AG Process for making benzoxazepin compounds
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
HRP20181392T1 (hr) * 2013-03-15 2018-10-19 Plexxikon Inc. Heterociklični spojevi i njihova uporaba
CN105873439A (zh) 2013-10-15 2016-08-17 詹森药业有限公司 RORγt的烷基连接的喹啉基调节剂
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015134854A2 (en) * 2014-03-06 2015-09-11 Oyagen, Inc. Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics
JP6543268B2 (ja) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
EP3180335B1 (en) 2014-08-11 2021-05-05 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
CN107531631B (zh) 2014-12-31 2021-09-03 安吉昂生物医药公司 用于治疗疾病的方法和药剂
BR112017020952A2 (pt) * 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
CN107922396B (zh) 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN113861198B (zh) * 2020-06-30 2024-08-02 上海医药集团股份有限公司 咪唑并[4,5-b]吡嗪类化合物、其制备方法及应用
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002251266A1 (en) 2001-04-10 2002-10-28 Merck Sharp And Dohme Limited Inhibitors of akt activity
WO2002083139A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US7337831B2 (en) * 2001-08-10 2008-03-04 Yokohama Tlo Company Ltd. Heat transfer device
HUE030390T2 (en) * 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso

Similar Documents

Publication Publication Date Title
JP2010507578A5 (enExample)
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
NZ592477A (en) Pyrazolylaminopyridines as inhibitors of fak
EP1952825A4 (en) NANOMETER-ORIENTED MEDICAMENT FOR THE MAGNETIC THERMOTHERAPY OF MALIGNEN TUMORS
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
CY1119217T1 (el) Ενωση για την αγωγη του καρκινου
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
AU2009270856A8 (en) Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
UA100684C2 (uk) Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
WO2007013950A3 (en) Combination therapy of her expressing tumors
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
EA200901611A1 (ru) Производные 2-оксо-3-бензил-бензоксазол-2-она и родственные соединения в качестве ингибиторов мет киназы для лечения опухолей
CL2009000443A1 (es) Compuestos derivados de 3-metil-imidazo-[1,2-b]-piridazina, moduladores de cinasa de tirosina c-met; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades proliferativas como tumores solidos, metastasis, cancer renal, cancer de cabeza y cuello. cancer pulmon.
EP2274437A4 (en) COMPOSITIONS AND METHODS FOR DETECTING EGFR MUTATIONS IN CANCER
JP2009527464A5 (enExample)
EA200901603A1 (ru) Арил-эфирные производные пиридазинона
WO2007117161A1 (en) Substituted ring fused azines and their use in cancer therapy
MX2009011421A (es) Derivados de ftalazina e isoquinolina con actividades moduladoras del receptor de la s1p.
MX2009006075A (es) Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes.
WO2007090022A3 (en) Novel compounds for targeting endothelial cells, compositions containing the same and methods for their use
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2006137009A3 (en) Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as therapeutic and diagnostic agents
WO2007016352A3 (en) Oral liquid losartan compositions